(Source: Ablynx NV) 7774bf26-b185-44c3-b7a5-30f44b343fd8.pdf ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM A PHASE IIb STUDY OF ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB (ALX-0061), AS A MONOTHERAPY IN RA ACR20, ACR50 and ACR70 scores of up to 81%, 49% and 24% respectively at week 12 Very encouraging efficacy data compared to tocilizumab with up to 41% of patients in clinical remission at week 12 Favourable safety profile, based on initial data, at all administered doses Results from the 24 week Phase IIb study of vobarilizumab, as a combination therapy with methotrexate in RA, are expected later in Q3 2016 Conference call and webcast today at 4pm CET/10am ET GHENT, Belgium, 7 July 2016 -...
↧